ºÚÁÏÍø

Hansa Biopharma has announced its attendance at the 43rd Annual J.P. Morgan Healthcare Conference, following significant achievements across three therapeutic areas in the past 12 months. In Autoimmune, the company reported positive data from the Phase 2 trial in Guillain Barre Syndrome and completed enrollment for the Phase 3 anti-GBM trial. Their second-generation IgG cleaving molecule, HNSA-5487, showed promising 12-month analysis results.

In Gene Therapy, Hansa initiated two significant trials: a Phase 1b trial in Duchenne Muscular Dystrophy with Sarepta Therapeutics and a Phase 2 trial in Crigler-Najjar Syndrome with Genethon. The Transplantation segment saw completion of ConfIdeS trial randomization and record-breaking IDEFIRIX quarterly sales of 69.5 MSEK in Q3 2024.

Key 2025 milestones include data readouts from multiple trials and a planned BLA submission to the FDA in the second half of the year. The company continues to develop novel immunomodulating therapies based on its proprietary IgG cleaving platform.

Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The company's senior management will deliver a presentation on Monday, January 13, 2025, at 12:00 p.m. ET / 9:00 a.m. PT.

The presentation will be followed by a Q&A session starting at 12:20 p.m. ET / 9:20 a.m. PT. Investors and interested parties can access the live webcast through the Events & Presentations section of Sarepta's investor relations website. The presentation recording will remain available on the website for 90 days afterward. Attendees are advised to connect early to allow time for any necessary software downloads.

Sarepta Therapeutics (NASDAQ:SRPT) has awarded equity incentives to 8 new employees hired in December 2024. The company granted a total of 10,660 restricted stock units (RSUs) as employment inducement awards. These RSUs will vest over four years, with 25% vesting annually on each anniversary of the December 31, 2024 grant date. The equity awards were approved by the Compensation Committee under Sarepta's 2024 Employment Commencement Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics (NASDAQ:SRPT) has completed enrollment and dosing in EMERGENE (Study SRP-9003-301), a Phase 3 clinical trial of SRP-9003 for treating limb-girdle muscular dystrophy Type 2E/R4. The global study's primary endpoint focuses on beta-sarcoglycan protein expression, with data expected in the first half of 2025.

The company plans to file for accelerated approval of SRP-9003 in 2025, following a positive pre-Biologics License Application meeting. This development serves as a precedent for Sarepta's other LGMD pipeline programs, including LGMD2D and LGMD2C programs, scheduled to initiate in Q1 2025.

Sarepta Therapeutics (NASDAQ:SRPT) has granted equity awards to 14 new employees hired in November 2024. The awards, approved under the company's 2024 Employment Commencement Incentive Plan, consist of 8,040 restricted stock units (RSUs). These RSUs will vest over four years, with one-fourth vesting annually on the grant date anniversary. The equity awards were granted as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).

Arrowhead Pharmaceuticals announced a global licensing and collaboration agreement with Sarepta Therapeutics. The deal includes an immediate $825 million payment ($500M cash + $325M equity investment at 35% premium), plus $250 million over five years. Arrowhead is eligible for $300 million in near-term clinical trial milestone payments and up to $10 billion in future milestones plus royalties.

The agreement covers multiple clinical and preclinical programs in rare genetic diseases affecting muscle, CNS, and lungs. Sarepta can select up to six new targets using Arrowhead's TRiMâ„¢ platform. The transaction extends Arrowhead's cash runway into 2028 and is expected to close in early 2025.

Sarepta Therapeutics announces a global licensing and collaboration agreement with Arrowhead Pharmaceuticals for multiple siRNA programs. Sarepta will obtain exclusive worldwide rights to four clinical-stage and three preclinical-stage programs targeting muscle, CNS, and rare pulmonary disorders. The deal includes a $500 million upfront payment and $325 million equity investment at a 35% premium to Arrowhead, plus future milestone payments and royalties. Additionally, both companies entered a discovery partnership for six targets. Sarepta's Board has approved a $500 million share repurchase program. The transaction is expected to close in early 2025.

Sarepta Therapeutics reported strong financial results for Q3 2024, with net product revenues totaling $429.8 million, a 39% increase YoY. ELEVIDYS net product revenue was $181.0 million, exceeding prior guidance, with an additional $9.5 million from Roche's sales royalties. Total ELEVIDYS performance reached $190.5 million for the quarter. The company achieved GAAP and non-GAAP net incomes of $33.6 million and $67.0 million respectively. Sarepta also announced the discontinuation of the SRP-5051 development program and shared positive data from its SRP-9001 clinical trials. The CEO highlighted the progress in their pipeline, including plans to submit a Biologics License Application by mid-2025 and start clinical trials for two other programs. The company also published five-year functional results from Study SRP-9001-101 and EMBARK study results in Nature Medicine, showing clinical benefits and favorable safety profiles. For the nine months ended September 30, 2024, total revenues were $1.24 billion, a 47% increase YoY.

Sarepta Therapeutics (NASDAQ:SRPT) has granted equity awards to 15 new employees hired in October 2024. The awards, consisting of 12,165 restricted stock units (RSUs), were approved by the Compensation Committee under the company's 2024 Employment Commencement Incentive Plan. The RSUs will vest over four years, with one-fourth vesting annually on the grant date anniversary. Sarepta, a leader in precision genetic medicine for rare diseases, maintains leadership positions in Duchenne muscular dystrophy and limb-girdle muscular dystrophies, with over 40 programs in development.